Innovative Technology Adoption Calcivis has developed and gained FDA approval for its cutting-edge bioluminescent dental imaging system, enabling real-time chairside assessment of enamel demineralization. This innovative technology offers a compelling solution for practitioners seeking to enhance preventive care and improve patient outcomes.

Expanding US Presence With the recent establishment of its US headquarters in Milton, Massachusetts, and key hires in sales and marketing, Calcivis is strategically positioned to target American dental clinics and expand its market share through direct engagement and localized support.

Strategic Industry Engagement Calcivis has appointed experienced non-executive directors and senior commercial staff, demonstrating its commitment to accelerating market penetration and building strategic partnerships within the dental and medical device sectors in the US.

Funding and Growth Potential Securing over $5 million USD from the Scottish National Investment Bank highlights investor confidence and provides a financial runway for sales expansion, product adoption campaigns, and scaling customer support efforts.

Market Opportunity The company focuses on preventive dentistry aimed at reducing costly surgical interventions, creating opportunities to collaborate with dental practices advocating minimally invasive care and early diagnostics, thus enabling a proactive approach that appeals to clinicians committed to patient-centered care.